Healthcare Industry News: Magnetoencephalography
News Release - May 8, 2007
Elekta Neuromag and Innokas Medical in Agreement on Production OutsourcingSTOCKHOLM, Sweden--(HSMN NewsFeed)--Elekta Neuromag Oy, the Finnish subsidiary of the Swedish Elekta Group (STO:EKTAB), and Innokas Medical Oy, a Finnish private company, have signed an agreement covering production of the Elekta Neuromag® Magnetoencephalography (MEG) system. The Elekta Neuromag MEG system is used for non-invasive real-time measurements of brain activity at leading research institutions and hospitals around the world. The production, including the employees involved, will be transferred to Innokas Medical during 2007.
Elekta is reinforcing its operations in the MEG business area due to the changing market situations and the increased need for Elekta's MEG technology. By outsourcing its MEG production to Innokas Medical, Elekta will get the benefit of a flexible and expert medical equipment production partner, while keeping the overall technical responsibility of the MEG system towards the customer. Elekta will continue to invest in innovation and fulfilling the customers' needs in the MEG area.
For Innokas Medical, this agreement is an important step in its growth strategy. It will strengthen the company's position as a leading medical equipment contract manufacturer in Finland.
"Non-invasive, real-time brain mapping and monitoring is considered as one of the most exciting developments in neuroscience today and the list of new applications for MEG is steadily growing and the number of installations are increasing," said Tomas Puusepp, President and CEO of Elekta. "Elekta is the only MEG vendor on the market with the financial stability needed to be committed to the long-term development of MEG technology and our production outsourcing agreement with Innokas Medical further strengthen our ability to serve neuroscience centers around the world with leading MEG technology."
Elekta is an international medical-technology Group, providing meaningful clinical solutions, comprehensive information systems and services for improved cancer care and management of brain disorders. All of Elekta's solutions employ non-invasive or minimally invasive techniques and are therefore clinically effective, gentle on the patient and cost-effective.
Clinical solutions include among others Leksell Gamma Knife® for non-invasive treatment of brain disorders and Elekta Synergy® for image guided radiation therapy (IGRT). Following the acquisition of IMPAC Medical Systems Inc. in April 2005, the Elekta Group is the world's largest supplier of oncology software.
Elekta's systems and solutions are used at over 4,000 hospitals around the world to treat cancer and manage clinical operations as well as to diagnose and treat brain disorders, including tumors, vascular malformations and functional disorders.
With approx. 2,000 employees, Elekta's corporate headquarter is located in Stockholm, Sweden and the company is listed on the Stockholm Stock Exchange under the ticker EKTAb. For more information about Elekta, please visit www.elekta.com.
About Innokas Medical Oy
Innokas Medical is a medical business company, founded in 1994, offering contract design and manufacturing services to its customers. The customers are well known international companies; many are market leaders in their own segment. The mission of Innokas Medical is to produce health care products behind these brands. The most important cornerstones of all company's activities are the unconditional quality of its products and services and the commitment to the industry and to fulfill its special requirements. Innokas Medical's quality system is certified according to ISO standards 9001:2000 and 13485:2003. The headquarter of the company is located in Kempele, close to Oulu, and it has manufacturing sites in Helsinki and Estonia. The sales of the company were 5.3 MEUR in 2006 and it has approx 70 employees. More information at www.innokasmedical.fi
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.